Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers

References

• Andersson T, Weidolf L. (2008). Stereoselective disposition of proton pump inhibitors. Clin Drug Investig 28:263–279.
   PubMed Web of Science ®Google Scholar
• Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I. (2001). Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169–174.
   PubMed Web of Science ®Google Scholar
• Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. (1999). OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866–871.
   PubMed Web of Science ®Google Scholar
• Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, Eichelbaum M, Fromm MF. (2002). MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 53:526–534.
   PubMed Web of Science ®Google Scholar
• Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W, Leake BF, Tirona RG, Kim RB. (2007). Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 81:362–370.
   PubMed Web of Science ®Google Scholar
• Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD. (2001). The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 69:114–121.
   PubMed Web of Science ®Google Scholar
• Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y. (2004). Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol 143:856–864.
   PubMed Web of Science ®Google Scholar
• Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, Kigawa J, Suzuki H, Nanba E, Oshimura M, Terakawa N, Otsubo K, Mine K, Sugiyama Y. (2005). Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 33:94–101.
   PubMed Web of Science ®Google Scholar
• Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B. (2001). Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120:525–533.
   PubMed Web of Science ®Google Scholar
• Lee W, Glaeser H, Smith LH, Roberts RL, Moeckel GW, Gervasini G, Leake BF, Kim RB. (2005). Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem 280:9610–9617.
   PubMed Web of Science ®Google Scholar
• Matsushima S, Maeda K, Ishiguro N, Igarashi T, Sugiyama Y. (2008). Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 36:663–669.
   PubMed Web of Science ®Google Scholar
• Miura M. (2006). Enantioselective disposition of lansoprazole and rabeprazole in human plasma. Yakugaku Zasshi 126:395–402.
   PubMed Web of Science ®Google Scholar
• Miura M, Uno T, Tateishi T, Suzuki T. (2007). Determination of fexofenadine enantiomers in human plasma with high-performance liquid chromatography. J Pharm Biomed Anal 43:741–745.
   PubMed Web of Science ®Google Scholar
• Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y. (2006). Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 82:1074–1084.
   PubMed Web of Science ®Google Scholar
• Niemi M, Kivistö KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF. (2005). Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol 59:602–604.
   PubMed Web of Science ®Google Scholar
• Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, Tsuji A, Yokoi T. (2002). Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 302:804–813.
   PubMed Web of Science ®Google Scholar
• Perloff MD, von Moltke LL, Greenblatt DJ. (2002). Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. J Clin Pharmacol 42:1269–1274.
   PubMed Web of Science ®Google Scholar
• Robbins DK, Castles MA, Pack DJ, Bhargava VO, Weir SJ. (1998). Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. Biopharm Drug Dispos 19:455–463.
   PubMed Web of Science ®Google Scholar
• Sakugawa T, Miura M, Hokama N, Suzuki T, Tateishi T, Uno T. (2009). Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. Br J Clin Pharmacol 67:535–540.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Fuse K, Okudaira K, Nishigaki R, Maeda K, Kusuhara H, Sugiyama Y. (2005). Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 33:1477–1481.
   PubMed Web of Science ®Google Scholar
• Simpson K, Jarvis B. (2000). Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 59:301–321.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Imamura N, Oguma N, Shintani T, Tanaka K, Hyodo H, Oda K, Kimura A. (2001). Acute myelogenous leukemia with PIG-A gene mutation evolved from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome. Int J Hematol 73:206–212.
   PubMed Web of Science ®Google Scholar
• Tateishi T, Miura M, Suzuki T, Uno T. (2008). The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. Br J Clin Pharmacol 65:693–700.
   PubMed Web of Science ®Google Scholar
• Tian X, Zamek-Gliszczynski MJ, Li J, Bridges AS, Nezasa K, Patel NJ, Raub TJ, Brouwer KL. (2008). Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice. Drug Metab Dispos 36:61–64.
   PubMed Web of Science ®Google Scholar
• Tsujimoto M, Hirata S, Dan Y, Ohtani H, Sawada Y. (2006). Polymorphisms and linkage disequilibrium of the OATP8 (OATP1B3) gene in Japanese subjects. Drug Metab Pharmacokinet 21:165–169.
   PubMed Web of Science ®Google Scholar
• Wu L, Xu X, Shen J, Xie H, Yu S, Liang T, Wang W, Shen Y, Zhang M, Zheng S. (2007). MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular carcinoma after liver transplantation. J Surg Oncol 96:62–68.
   PubMedGoogle Scholar
• Yi SY, Hong KS, Lim HS, Chung JY, Oh DS, Kim JR, Jung HR, Cho JY, Yu KS, Jang IJ, Shin SG. (2004). A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin Pharmacol Ther 76:418–427.
   PubMed Web of Science ®Google Scholar